

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental notice.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

SUPPLEMENTAL NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING IN 2021

Reference is made to the notice of the first extraordinary general meeting in 2021 (the “**EGM**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 16 August 2021 (the “**First Notice**”), which set out the time and place of the EGM and contained the relevant resolutions to be proposed to the Shareholders at the EGM for their consideration. Unless otherwise indicated, capitalized terms used herein shall have the same meaning as those defined in the supplemental circular of the Company dated 31 August 2021 (the “**Supplemental Circular**”).

SUPPLEMENTAL NOTICE IS HEREBY GIVEN that the EGM will be held as originally scheduled at the Conference Room of the Company, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC on Thursday, 30 September 2021 at 10:00 a.m., for the purpose of considering the following additional resolution, together with the other resolutions set out in the First Notice:

(1) To be considered and approved by way of ordinary resolution:

Resolution on postponement in fulfilling performance guarantee by the controlling shareholder and signing of supplemental agreement

The above proposed resolution was approved at the 15th meeting of the eighth session of the Board and the 11th meeting of the eighth session of the supervisory committee of the Company held on 18 August 2021.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 30 August 2021

Notes:

1. All times stated in this supplemental notice refer to Hong Kong time.
2. This supplemental notice should be read in conjunction with the First Notice, the First Circular and the Supplemental Circular.
3. Save for the inclusion of the New Resolution, there are no other changes to the resolutions set out in the First Notice. Please refer to the First Notice and the First Circular for details of other resolutions to be proposed at the EGM, closure of register of members, eligibility for attending the EGM, registration procedures for attending the EGM, the voting arrangements, the poll procedure and other relevant matters.
4. Form of Proxy

Since the First Proxy Form does not contain the additional resolution as set out in this supplemental notice, the Second Proxy Form has been prepared and is enclosed with this supplemental notice.

- (i) Holders of domestic shares (A shares) and overseas listed foreign shares (H shares) whose names appear on the register of members of the Company after the end of the trading hours on Tuesday, 31 August 2021 (including those holders of H shares who have submitted verified application documents for the transfer of shares on or before Tuesday, 31 August 2021 are entitled to attend the EGM. The register of members of the Company will be closed from Wednesday, 1 September 2021 to Thursday, 30 September 2021 (both days inclusive) as originally scheduled for the purpose of determining the entitlements of the Shareholders to attend the EGM, during which no transfer of H shares will be effected. In order to qualify to attend the EGM, all transfers, accompanied by the relevant share certificates, must be lodged with the Company's H Share Registrar, Hong Kong Registrars Limited, at Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong no later than 4:30 p.m. on Tuesday, 31 August 2021.
- (ii) Any shareholder entitled to attend and vote at the EGM is entitled to appoint one or more proxies (whether or not he/she is a shareholder) to attend and vote at the meeting on his/her behalf. If any shareholder appoints more than one proxy, the proxies can only vote by poll. In order to be valid, the proxy form and the notarially certified power of attorney and/or other documents of authorization (if any) must be delivered to the address of the Company's office (for holders of A shares) or the office address of the Company's H share Registrar, Hong Kong Registrars Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H shares) not less than 24 hours before the time appointed for the holding of the EGM or any adjournment thereof.
- (iii) Holders of H Shares who have lodged the First Proxy Form should note that:
 - (a) If the Second Proxy Form is lodged with the office of the Company's H Share Registrar 24 hours prior to the time designated for convening the EGM (the "**Closing Time**"), the Second Proxy Form will revoke and supersede the First Proxy Form previously lodged by him/her. The Second Form of Proxy will be treated as a valid form of proxy lodged by the holder of H Shares if correctly completed and signed and returned in accordance with the instructions printed thereon.

- (b) If no Second Proxy Form is lodged with the office of the Company's H Share registrar as at the Closing Time, the First Proxy Form will be treated as a valid form of proxy lodged by the holder of H Shares if correctly completed. The proxy so appointed by the holder of H Shares will be entitled to vote at his/her discretion or to abstain from voting on any resolution properly put to the EGM, including the New Resolution.
 - (c) Completion and return of the First Proxy Form and/or the Second Proxy Form applicable to the EGM will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish and in such event, the First Proxy Form and/or the Second Proxy Form shall be deemed to have revoked.
5. To attend the EGM, an individual shareholder should bring along his/her identity card, shareholder account card; a proxy should bring along the proxy form, his/her identity card and the identity card of the principal and the shareholder account card for registration purpose. A legal person shareholder should bring along a copy of the business license, the proxy form signed by the legal entity, the shareholder account card and the identity card of the attendee for registration purpose.

6. Place and time of registration:

Registration date and time: 9:30 a.m.-11:30 a.m. and 2:00 p.m.-4:30 p.m. on 10 September 2021 (Friday)

Place of registration: Office of the secretariat to the Board, 2nd Floor, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC

7. Address: 2nd Floor of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, 45 Sha Mian North Street, Liwan District, Guangzhou City, Guangdong Province, the PRC

Postal code: 510130

Contact person: Huang Ruimei/Li Li

Tel: (8620) 6628 1216/6628 1219

Fax: (8620) 6628 1229

Email: sec@gybys.com.cn

Address of Shanghai Branch of China Securities Depository and Clearing Corporation Limited: No. 188 Yanggaonan Road, Pudong New Area, Shanghai, the PRC

Address of Hong Kong Registrars Limited: Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for submitting share transfer documents)

17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for submitting reply slips or proxy forms)

8. The EGM is expected to last for half day. Shareholders attending the EGM shall be responsible for their own travelling and accommodation expenses.
9. Reporters attending the EGM shall register before the registration time for the shareholders.

As at the date of this supplemental notice, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin and Mr. Huang Min as independent non-executive directors.